Mitchell Ho has pioneered the production of inhibitory antibodies that target tumor-specific heparan sulfate proteoglycans. His laboratory studies glypicans as a novel class of therapeutic targets and identifies single domain antibodies that have the unique ability to bind cryptic functional regions in extracellular signaling complexes. Several promising antibody therapeutics are being developed for clinical use, including ones that inhibits glypican-3/Wnt signaling in liver cancer.
Dr. Ho serves on the Board of Distinguished Advisors for the Antibody Society. He is the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH.